

## CLINICAL TRIALS COMMITTEE MEMBERSHIP

01 May 2019

Name	Role and Primary Specialty	City
Brett Clelland, JD	Law (Intellectual Property)	Edmonton
Albert de Villiers, MD	Scientific (Medical Officer / Family Physician)	Grande Prairie
Sunil Desai, MD (Acting Chair)	Scientific (Pediatric Hematology, Oncology)	Edmonton
Jennifer Guillemaud, MD	Scientific (Otolaryngology)	Calgary
Jamie Hodge, P.Eng.	Community Member	Calgary
John Kennedy, MD, FRCPC	Scientific (Psychiatry)	Edmonton
Larry Loomes	Community Member	Foothills
Jodi Parrotta, MA, CCRP	Non-Scientific (Regulations)	Edmonton
Nimesh Patel, MPH	Scientific (Quantitative Methodology)	Lethbridge
Andrew Ross, PhD	Ethics (Clinical Ethics)	Edmonton
Peter Venner, MD (Acting Vice-	Scientific (Medical Oncology)	Edmonton
Chair)		

The HREBA Clinical Trials Committee (CTC) is constituted and operates in accordance with the:

- Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2, 2014);
- Alberta Health Information Act (HIA);
- Good Clinical Practice (GCP) Guidelines of the International Conference on Harmonization (ICH);
- Health Canada's Food and Drug Regulations (FDR), Part C, Division 5.

The committee is registered with the U.S Department of Health and Human Services, Office for Human Research Protections (OHRP), IRB # 00001209.

The HREBA-CTC is one of three committees which comprise the HIA-designated Health Research Ethics Board of Alberta. Since the three committees operate as one Research Ethics Board, members from one committee may attend another committee's meeting when their expertise is required. This ensures that members in attendance have the specific expertise, relevant competence and knowledge necessary to provide an adequate research ethics review of the proposals under consideration.

The majority of the committee members are Canadian citizens or permanent residents under the Immigration and Refugee Protection Act. Members named as Principal Investigators or Co-investigators on a study that is under review do not participate in discussions related to, nor vote on, such studies when they are presented; this applies to initial and continuing reviews.